Dr. Agarwal's Eye Hospital Limited has announced its unaudited financial results for the quarter ended December 31, 2025, demonstrating solid performance across key metrics. The specialized eye care provider also announced the relocation of its registered office within Chennai to facilitate better administrative convenience and infrastructure requirements.

Q3FY26 Financial Performance

The company's third quarter performance for FY26 shows steady growth compared to the corresponding period in the previous year, with improvements in revenue and profitability metrics.

Nine Months Performance FY26

For the nine months ended December 31, 2025, the company maintained strong momentum with significant year-on-year improvements across all major financial parameters.

Corporate Development

The Board of Directors approved the shifting of the company's registered office within the local limits of Chennai. The registered office will be relocated from 3rd Floor, Buhari Towers, No.4, Moores Road, Off. Greams Road, Chennai, Tamil Nadu- 600 006 to 6th Floor, 1st Main Road, Austin Nagar, Alwarpet, Chennai, Tamil Nadu 600 018 with effect from February 05, 2026.

Board Meeting and Compliance

The Board of Directors meeting was held on February 03, 2026, where they approved the unaudited financial results along with the limited review report from statutory auditors. The meeting commenced at 02:00 p.m. and concluded at 02:55 p.m. The financial results will be published in newspapers in compliance with SEBI regulations and are available on the company's website at www.dragarwal.com .

Dr. Agarwal's Eye Hospital , a leading eye care provider, has announced its financial results for the quarter and half-year ended September 30, 2023, along with several key corporate decisions.

Financial Results and Dividend Declaration

The Board of Directors has approved the unaudited financial results for the quarter and half-year ended September 30, 2023. The company has declared an interim dividend of ₹3 per equity share of ₹10 each for the financial year 2023-24.

Key details of the dividend:

• Amount: ₹3 per equity share (30% on face value of ₹10)
• Record Date: November 7, 2023
• Payment Date: On or before November 29, 2023

Shareholders whose names appear on the Register of Members or in the records of the depositories as beneficial owners on the record date will be eligible to receive the dividend.

Proposed Amalgamation

The Board has approved a proposed scheme of amalgamation with Dr. Agarwal's Health Care Limited. This decision is subject to necessary shareholder and regulatory approvals.

Preferential Issue of Shares

The company has completed a preferential issue of 4,32,827 equity shares at ₹5,270 per share to Dr. Agarwal's Health Care Limited. These shares were allotted on September 26, 2023. The proceeds from this preferential allotment are currently invested in debt mutual funds, pending utilization.

Business Segment

Dr. Agarwal's Eye Hospital operates in a single segment of eye care related sales and services.

Corporate Governance

The company has adhered to regulatory requirements by promptly disclosing the outcome of its Board meeting. The unaudited financial results for the quarter and half-year ended September 30, 2023, have been approved by the Board.

These developments, including the interim dividend declaration, proposed amalgamation, and successful preferential share issue, reflect Dr. Agarwal's Eye Hospital's corporate strategy and commitment to shareholder value.